Chi Sheng Pharma & Biotech 過去の業績
過去 基準チェック /26
Chi Sheng Pharma & Biotech has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 2.3% per year. Chi Sheng Pharma & Biotech's return on equity is 6.1%, and it has net margins of 6.8%.
主要情報
13.9%
収益成長率
13.9%
EPS成長率
| Pharmaceuticals 業界の成長 | 18.5% |
| 収益成長率 | 2.3% |
| 株主資本利益率 | 6.1% |
| ネット・マージン | 6.8% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10収支内訳
Chi Sheng Pharma & Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 1,082 | 73 | 266 | 20 |
| 31 Mar 24 | 1,065 | 73 | 262 | 21 |
| 31 Dec 23 | 1,061 | 69 | 260 | 22 |
| 30 Sep 23 | 1,090 | 116 | 265 | 23 |
| 30 Jun 23 | 1,115 | 151 | 262 | 22 |
| 31 Mar 23 | 1,130 | 164 | 254 | 20 |
| 31 Dec 22 | 1,143 | 179 | 249 | 20 |
| 30 Sep 22 | 1,105 | 186 | 227 | 18 |
| 30 Jun 22 | 1,085 | 150 | 219 | 19 |
| 31 Mar 22 | 1,059 | 129 | 219 | 19 |
| 31 Dec 21 | 1,022 | 108 | 219 | 19 |
| 30 Sep 21 | 1,003 | 56 | 233 | 19 |
| 30 Jun 21 | 971 | 41 | 235 | 19 |
| 31 Mar 21 | 953 | 46 | 231 | 19 |
| 31 Dec 20 | 979 | 59 | 229 | 18 |
| 30 Sep 20 | 1,005 | 72 | 228 | 19 |
| 30 Jun 20 | 1,026 | 80 | 227 | 19 |
| 31 Mar 20 | 1,047 | 85 | 234 | 20 |
| 31 Dec 19 | 1,023 | 72 | 232 | 21 |
| 30 Sep 19 | 998 | 57 | 233 | 22 |
| 30 Jun 19 | 985 | 57 | 233 | 22 |
| 31 Mar 19 | 964 | 46 | 229 | 22 |
| 31 Dec 18 | 967 | 42 | 229 | 23 |
| 30 Sep 18 | 985 | 52 | 227 | 24 |
| 30 Jun 18 | 1,016 | 60 | 227 | 24 |
| 31 Mar 18 | 1,032 | 69 | 222 | 23 |
| 31 Dec 17 | 1,045 | 82 | 219 | 23 |
| 30 Sep 17 | 1,034 | 91 | 213 | 20 |
| 30 Jun 17 | 1,012 | 88 | 209 | 19 |
| 31 Mar 17 | 995 | 85 | 209 | 19 |
| 31 Dec 16 | 964 | 73 | 207 | 19 |
| 30 Sep 16 | 946 | 48 | 210 | 25 |
| 30 Jun 16 | 936 | 46 | 207 | 26 |
| 31 Mar 16 | 938 | 42 | 203 | 25 |
| 31 Dec 15 | 932 | 39 | 203 | 26 |
| 30 Sep 15 | 908 | 40 | 191 | 20 |
| 30 Jun 15 | 922 | 50 | 187 | 18 |
| 31 Mar 15 | 925 | 59 | 184 | 19 |
| 31 Dec 14 | 943 | 73 | 178 | 18 |
| 30 Sep 14 | 979 | 104 | 177 | 18 |
| 30 Jun 14 | 974 | 105 | 176 | 17 |
| 31 Mar 14 | 960 | 106 | 173 | 16 |
| 31 Dec 13 | 921 | 96 | 171 | 16 |
質の高い収益: 4111 has high quality earnings.
利益率の向上: 4111's current net profit margins (6.8%) are lower than last year (13.6%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 4111's earnings have grown by 13.9% per year over the past 5 years.
成長の加速: 4111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
収益対業界: 4111 had negative earnings growth (-51.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
株主資本利益率
高いROE: 4111's Return on Equity (6.1%) is considered low.